Meet the "Magnificent Seven" Stock That Pays More Dividends Than Any Other U.S.-Based Company
https://www.fool.com/investing/2024/03/16/magnificent-seven-stock-pays-most-dividends/?source=iedfolrf0000001
Mar 16, 2024 - Microsoft is the complete package.
0
Lilly (LLY) Gets Second FDA Nod for Lymphoma Drug Jaypirca
https://www.zacks.com/stock/news/2193151/lilly-lly-gets-second-fda-nod-for-lymphoma-drug-jaypirca?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2193151
Dec 04, 2023 - Following the latest approval, Lilly's (LLY) Jaypirca is the first and the only non-covalent BTK inhibitor to extend the benefit of targeting the BTK pathway.
0
Pharma Stock Roundup: ABBV to Buy CERE, JNJ's 2024 View, LLY & NVS Get FDA Nod
https://www.zacks.com/stock/news/2195315/pharma-stock-roundup-abbv-to-buy-cere-jnj-s-2024-view-lly-nvs-get-fda-nod?cid=CS-ZC-FT-analyst_blog|stock_roundup-2195315
Dec 08, 2023 - AbbVie (ABBV) offers to acquire Cerevel Therapeutics for $8.7 billion. J&J (JNJ) announces sales and earnings growth expectations for 2024.
0
Is iShares Core High Dividend ETF (HDV) a Strong ETF Right Now?
https://www.zacks.com/stock/news/2203479/is-ishares-core-high-dividend-etf-hdv-a-strong-etf-right-now?cid=CS-ZC-FT-smart_beta_etf-2203479
Dec 29, 2023 - Smart Beta ETF report for HDV
0
Top Analyst Reports for Johnson & Johnson, Micron Technology & Southern Company
https://www.zacks.com/commentary/2208227/top-analyst-reports-for-johnson-johnson-micron-technology-southern-company?cid=CS-ZC-FT-research_daily-2208227
Jan 10, 2024 - Today's Research Daily features new research reports on 16 major stocks, including Johnson & Johnson (JNJ), Micron Technology, Inc. (MU) and The Southern Company (SO).
0
Johnson & Johnson (JNJ) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
https://www.zacks.com/stock/news/2214282/johnson-johnson-jnj-q4-earnings-taking-a-look-at-key-metrics-versus-estimates?cid=CS-ZC-FT-fundamental_analysis|nfm-2214282
Jan 23, 2024 - The headline numbers for Johnson & Johnson (JNJ) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
0
Key Takeaways From JNJ's (JNJ) Q4 Earnings Presentation
https://www.zacks.com/stock/news/2216453/key-takeaways-from-jnj-s-jnj-q4-earnings-presentation?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2216453
Jan 26, 2024 - J&J's (JNJ) Innovative Medicines as well as MedTech units outperform expectations in the fourth quarter. Here we discuss some highlights of its performance in the fourth quarter.
0
AbbVie (ABBV) Q4 Earnings Beat, Raises Sales View for Key Drugs
https://www.zacks.com/stock/news/2220511/abbvie-abbv-q4-earnings-beat-raises-sales-view-for-key-drugs?cid=CS-ZC-FT-analyst_blog|earnings_article-2220511
Feb 02, 2024 - AbbVie???s (ABBV) fourth-quarter earnings and sales beat estimates. Management hikes the 2027 forecast for new immunology drugs to more than $27 billion.
0
Top Research Reports for Johnson & Johnson, Walt Disney & Uber
https://www.zacks.com/commentary/2223994/top-research-reports-for-johnson-johnson-walt-disney-uber?cid=CS-ZC-FT-research_daily-2223994
Feb 09, 2024 - Today's Research Daily features new research reports on 16 major stocks, including Johnson & Johnson (JNJ), The Walt Disney Company (DIS) and Uber Technologies, Inc. (UBER).
0
J&J (JNJ) Secures Full FDA Nod for Rybrevant in Lung Cancer
https://www.zacks.com/stock/news/2235489/j-j-jnj-secures-full-fda-nod-for-rybrevant-in-lung-cancer?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2235489
Mar 04, 2024 - The approval is based on data from a late-stage study wherein treatment with J&J's (JNJ) Rybrevant plus chemotherapy reduced the disease-progression risk or death by 61% in certain NSCLC patients.
0